Search

Displaying results 3071 - 3080 of 10000 in total
  1. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. … In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma.

  3. Drug

    Luvometinib

    go.drugbank.com/drugs/DB21696
    Investigational

    Luvometinib has a monoisotopic molecular weight of 665.04 Da. … Luvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration).

  4. Drug

    Passiflora incarnata flower

    go.drugbank.com/drugs/DB13974
    Approved

    Synonyms: Passiflora incarnata flower dry extractMixtures: Bio-strath No. 8 Gouttes
  5. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.

  6. Drug

    Vanadium

    go.drugbank.com/drugs/DB13971
    Approved

    Mixtures: Extra Once A Day, Maximum Once A Day
  7. Drug

    Alefacept

    go.drugbank.com/drugs/DB00092
    ApprovedWithdrawn

    Produced by CHO cells, mW is 91.4 kD.

  8. Drug

    Irinotecan

    go.drugbank.com/drugs/DB00762
    ApprovedInvestigational

    [A263376] Approved by the FDA in 1996,[A263366] irinotecan is used to treat colorectal cancer and pancreatic adenocarcinoma. … Both irinotecan and SN-38 mediate antitumor activity by forming a complex with topoisomerase I and blocking its enzymatic activity, thereby interfering with DNA synthesis.

  9. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal. … [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  10. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … [A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]